Supplementary Data from Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients

Supplementary Table S1. Antibodies used for flow cytometry staining. Supplementary Table S2. Clinical and immunological Characteristics of lost-to-follow up patients versus patients Supplementary Table S3. Patient data of patients whose blood was received for at least two time points. Patient characteristics, clinical response and immune populations after treatment. Supplementary Figure S1. Absolute numbers of immune cells per liter peripheral blood of NSCLC patients treated with chemotherapy. Supplementary Figure S2. Proportions of major T cell subsets in NSCLC patients treated with chemotherapy. Supplementary Figure S3. Monocyte subsets in peripheral blood of NSCLC patients treated with chemotherapy. Supplementary Figure S4. Co-inhibitory receptor expression on proliferating CD8 TEMRA cells in peripheral blood of chemotherapy-treated NSCLC patients. Supplementary Figure S5. Ki67+ CD8/ tumor burden ratio in NSCLC patients in relation to clinical outcome. Supplementary Figure S6. PD1 and CTLA4 expression on Tregs.